Literature DB >> 17700021

Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease.

Edmond Teng1, Po H Lu, Jeffrey L Cummings.   

Abstract

BACKGROUND: Neuropsychiatric disturbances are common in mild cognitive impairment (MCI). Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD.
METHODS: Fifty-one MCI subjects were assessed for neuropsychiatric symptoms using the Neuropsychiatric Inventory. Subjects were followed for an average of 2 years. Twelve subjects (23.5%) progressed from MCI to possible/probable AD and 39 subjects (76.5%) remained stable or improved. Baseline Neuropsychiatric Inventory indices were compared between groups.
RESULTS: Subjects progressing to AD had a significantly higher prevalence of psychopathology than subjects who remained stable or improved (100 vs. 59%). Depression (67 vs. 31%) and apathy (50 vs. 18%) were more common in subjects who were later diagnosed with AD. After statistical adjustments for other baseline demographic variables, these specific symptoms were less robust predictors of progression to AD than the presence of any psychopathology.
CONCLUSIONS: These findings suggest that neuropsychiatric symptoms in MCI are a predictor of progression to AD. Depression and apathy appear to be most useful for identifying MCI subjects at highest risk of developing dementia.

Entities:  

Mesh:

Year:  2007        PMID: 17700021     DOI: 10.1159/000107100

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  64 in total

1.  An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Authors:  John J Hanfelt; Joanne Wuu; Ann B Sollinger; Melanie C Greenaway; James J Lah; Allan I Levey; Felicia C Goldstein
Journal:  Am J Geriatr Psychiatry       Date:  2011-11       Impact factor: 4.105

2.  Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.

Authors:  Jeffrey L Cummings; John Ringman; Karen Metz
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Cognitive symptoms facilitatory for diagnoses in neuropsychiatric disorders: executive functions and locus of control.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

4.  Treatments for Depression in Older Persons with Dementia.

Authors:  Zvi D Gellis; Kimberly P McClive-Reed; Ellen Brown
Journal:  Ann Longterm Care       Date:  2009-02-02

5.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

6.  Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID).

Authors:  Nathan Herrmann; Tetsuhiro Harimoto; Robert Balshaw; Krista L Lanctôt
Journal:  Can J Psychiatry       Date:  2015-04       Impact factor: 4.356

Review 7.  The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?

Authors:  Adriana P Hermida; William M McDonald; Kyle Steenland; Allan Levey
Journal:  Expert Rev Neurother       Date:  2012-11       Impact factor: 4.618

8.  Non-cognitive psychopathological symptoms associated with incident mild cognitive impairment and dementia, Alzheimer's type.

Authors:  Antonio Lobo; Raúl López-Antón; Concepción de-la-Cámara; Miguel Angel Quintanilla; Antonio Campayo; Pedro Saz
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  Mild cognitive impairment: searching for the prodrome of Alzheimer's disease.

Authors:  Paul B Rosenberg; Constantine Lyketsos
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

Review 10.  Adverse stress, hippocampal networks, and Alzheimer's disease.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2009-11-27       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.